IV Busulfex

IV Busulfex

busulfan

Manufacturer:

Otsuka (Philippines)

Distributor:

Zuellig

Marketer:

Otsuka (Philippines)
Concise Prescribing Info
Contents
Busulfan
Indications/Uses
Allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia in combination w/ cyclophosphamide (conditioning regimen).
Dosage/Direction for Use
Premedicate w/ anticonvulsants (eg, benzodiazepines, phenytoin, valproic acid or levetiracetam) 12 hr prior to 24 hr after the last high dose of Busulfan. Administer antiemetics prior to 1st dose & continue on a fixed schedule. IV Patients >12 kg 0.8 mg/kg (ideal body wt or actual body wt, whichever is lower) via central venous catheter as a 2-hr infusion every 6 hr for 4 consecutive days for a total of 16 doses (day 4, 5, 6, & 7); cyclophosphamide 60 mg/kg IV as 1-hr infusion on each of 2 days beginning no >6 hr following the 16th dose of Busulfan (day 2 & 3); administer hematopoietic progenitor cells on Day 0.
Special Precautions
Prolonged myelosuppression, severe granulocytopenia, thrombocytopenia, anemia, or any combination may develop. High-dose oral busulfan may cause seizure; patients w/ history of seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs. High AUC values may be associated w/ increased risk of developing HVOD. Cardiac tamponade in ped patients w/ thalassemia who received high doses. Bronchopulmonary dysplasia w/ pulmonary fibrosis. Cytologic abnormalities characterized by giant, hyperchromatic nuclei in lymph nodes, pancreas, thyroid, adrenal glands, liver, lungs & bone marrow. Monitor complete blood counts, including WBC differentials & quantitative platelet counts daily during treatment & until engraftment is demonstrated. Monitor serum transaminases, alkaline phosphatase & bilirubin daily. Pregnancy & lactation. Childn.
Adverse Reactions
Myelosuppression, seizures, HVOD, embryo-fetal toxicity, cardiac tamponade, bronchopulmonary dysplasia, cellular dysplasia.
Drug Interactions
Decreased clearance w/ itraconazole, metronidazole, acetaminophen. Increased clearance w/ phenytoin.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01AB01 - busulfan ; Belongs to the class of alkylating agents, alkyl sulfonates. Used in the treatment of cancer.
Presentation/Packing
Form
IV Busulfex soln for IV infusion 6 mg/mL
Packing/Price
10 mL x 8 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in